115 related articles for article (PubMed ID: 10083982)
1. Oral bioavailability and pharmacokinetics of the new insulin sensitizer DRF-2189 in Wistar rats.
Jajoo HK; Mamidi RN; Vakkalanka SV; Sathyavageeswaran S; Katneni K; Ayalasomayajula PS; Rao BP; Lohray BB; Subramaniam S
Arzneimittelforschung; 1999 Feb; 49(2):133-6. PubMed ID: 10083982
[TBL] [Abstract][Full Text] [Related]
2. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
[TBL] [Abstract][Full Text] [Related]
3. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys.
Maeshiba Y; Kiyota Y; Yamashita K; Yoshimura Y; Motohashi M; Tanayama S
Arzneimittelforschung; 1997 Jan; 47(1):29-35. PubMed ID: 9037440
[TBL] [Abstract][Full Text] [Related]
4. Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats.
Mamidi RN; Katneni K; Mullangi R; Ramanujam R
Eur J Drug Metab Pharmacokinet; 2002; 27(3):175-8. PubMed ID: 12365198
[TBL] [Abstract][Full Text] [Related]
5. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of pioglitazone in Thai healthy subjects.
Wittayalertpanya S; Chompootaweep S; Thaworn N
J Med Assoc Thai; 2006 Dec; 89(12):2116-22. PubMed ID: 17214065
[TBL] [Abstract][Full Text] [Related]
7. High-performance liquid chromatographic determination of the insulin sensitizing agent DRF-2189 in rat plasma.
Jajoo HK; Rao Mamidi NV; Kasiram K; Prakash AS; Swaroop Kumar VV; Bheema Rao P; Bhushan V; Subramaniam S
J Chromatogr B Biomed Sci Appl; 1998 Apr; 707(1-2):241-6. PubMed ID: 9613956
[TBL] [Abstract][Full Text] [Related]
8. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.
von Nicolai H; Brickl R; Eschey H; Greischel A; Heinzel G; König E; Limmer J; Rupprecht E
Arzneimittelforschung; 1997 Mar; 47(3):247-52. PubMed ID: 9105542
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of pidotimod in rats and dogs.
Coppi G; Silingardi S
Arzneimittelforschung; 1994 Dec; 44(12A):1460-4. PubMed ID: 7857342
[TBL] [Abstract][Full Text] [Related]
10. Effect of pentoxifylline on the pharmacokinetics of rosiglitazone in Wistar rats.
Varanasi KK; Potharaju S; Rajak S; Veeraraghavan S; Mallick P; Vakkalanka SK
Methods Find Exp Clin Pharmacol; 2008 Sep; 30(7):537-42. PubMed ID: 18985182
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ebrotidine in rats and dogs.
Albet C; Pérez JA; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
[TBL] [Abstract][Full Text] [Related]
12. Novel euglycemic and hypolipidemic agents. 1.
Lohray BB; Bhushan V; Rao BP; Madhavan GR; Murali N; Rao KN; Reddy AK; Rajesh BM; Reddy PG; Chakrabarti R; Vikramadithyan RK; Rajagopalan R; Mamidi RN; Jajoo HK; Subramaniam S
J Med Chem; 1998 May; 41(10):1619-30. PubMed ID: 9572887
[TBL] [Abstract][Full Text] [Related]
13. High-performance liquid chromatographic determination of oxatomide and its metabolite and its application to pharmacokinetic study in rat plasma.
Kikuchi K; Ohishi T; Masuike T; Ohmori K; Sakai K
Arzneimittelforschung; 2002; 52(10):754-63. PubMed ID: 12442638
[TBL] [Abstract][Full Text] [Related]
14. Dose proportionality studies of novel thiazolidinedione derivatives as potent antidiabetic agents in mice.
Heitzmann T; Neidlein R; Freund P; Reiff K; Strein K
Arzneimittelforschung; 1995 Dec; 45(12):1284-8. PubMed ID: 8595085
[TBL] [Abstract][Full Text] [Related]
15. The effects of dose, route, and repeated dosing on the disposition and kinetics of tetrabromobisphenol A in male F-344 rats.
Kuester RK; Sólyom AM; Rodriguez VP; Sipes IG
Toxicol Sci; 2007 Apr; 96(2):237-45. PubMed ID: 17234645
[TBL] [Abstract][Full Text] [Related]
16. The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
Miller AK; DiCicco RA; Freed MI
Clin Ther; 2002 Jul; 24(7):1062-71. PubMed ID: 12182252
[TBL] [Abstract][Full Text] [Related]
17. Reduced prehepatic extraction of nicardipine in the presence of pioglitazone in rats.
Choi JS; Koh YY; Chung JH; Choi DH; Han HK
J Pharm Pharmacol; 2008 Oct; 60(10):1403-7. PubMed ID: 18812034
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent pharmacokinetics of a new Na+/H+ exchanger inhibitor KR-33028 in rats.
Kim YH; Yoo SD; Kim YS; Lee KH; Lee HS
Biopharm Drug Dispos; 2007 Nov; 28(8):423-9. PubMed ID: 17828714
[TBL] [Abstract][Full Text] [Related]
19. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
Zuo Z; Tam YK; Diakur J; Wiebe LI
J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach.
Izumi T; Enomoto S; Hosiyama K; Sasahara K; Shibukawa A; Nakagawa T; Sugiyama Y
J Pharmacol Exp Ther; 1996 Jun; 277(3):1630-41. PubMed ID: 8667232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
